



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Spinocerebellar ataxia with axonal neuropathy

Citation for published version:

Hirano, R, Interthal, H, Huang, C, Nakamura, T, Deguchi, K, Choi, K, Bhattacharjee, MB, Arimura, K, Umehara, F, Izumo, S, Northrop, JL, Salih, MAM, Inoue, K, Armstrong, DL, Champoux, JJ, Takashima, H & Boerkoel, CF 2007, 'Spinocerebellar ataxia with axonal neuropathy: consequence of a Tdp1 recessive neomorphic mutation?' EMBO Journal, vol 26, no. 22, pp. 4732-43., 10.1038/sj.emboj.7601885

Digital Object Identifier (DOI):

[10.1038/sj.emboj.7601885](https://doi.org/10.1038/sj.emboj.7601885)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher final version (usually the publisher pdf)

Published In:

EMBO Journal

Publisher Rights Statement:

Free in PMC.

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Spinocerebellar ataxia with axonal neuropathy: consequence of a Tdp1 recessive neomorphic mutation?

Ryuki Hirano^{1,2,10,11}, Heidrun Interthal^{3,11},
Cheng Huang⁴, Tomonori Nakamura⁵,
Kimiko Deguchi⁶, Kunho Choi^{1,2},
Meenakshi B Bhattacharjee⁶, Kimiyoshi
Arimura⁵, Fujio Umehara⁵, Shuji Izumo⁷,
Jennifer L Northrop⁴, Mustafa AM Salih⁸,
Ken Inoue⁹, Dawna L Armstrong⁶,
James J Champoux³, Hiroshi Takashima⁵
and Cornelius F Boerkoel^{1,2,*}

¹Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, University of British Columbia, Vancouver, British Columbia, Canada, ²Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada, ³Department of Microbiology, School of Medicine, University of Washington, Seattle, WA, USA, ⁴Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA, ⁵Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, ⁶Department of Pathology, Baylor College of Medicine, Houston, TX, USA, ⁷Division of Molecular Pathology, Center for Chronic Viral Disease, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, ⁸Division of Pediatric Neurology, Department of Pediatrics, College of Medicine, Riyadh, Saudi Arabia and ⁹Department of Mental Retardation and Birth Defect Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan

Tyrosyl-DNA phosphodiesterase 1 (Tdp1) cleaves the phosphodiester bond between a covalently stalled topoisomerase I (Topo I) and the 3' end of DNA. Stalling of Topo I at DNA strand breaks is induced by endogenous DNA damage and the Topo I-specific anticancer drug camptothecin (CPT). The H493R mutation of Tdp1 causes the neurodegenerative disorder spinocerebellar ataxia with axonal neuropathy (SCAN1). Contrary to the hypothesis that SCAN1 arises from catalytically inactive Tdp1, Tdp1^{-/-} mice are indistinguishable from wild-type mice, physiologically, histologically, behaviorally, and electrophysiologically. However, compared to wild-type mice, Tdp1^{-/-} mice are hypersensitive to CPT and bleomycin but not to etoposide. Consistent with earlier *in vitro* studies, we show that the H493R Tdp1 mutant protein retains residual activity and becomes covalently trapped on the DNA after CPT treatment of SCAN1 cells. This result provides a direct demonstration that Tdp1 repairs Topo I covalent lesions

*Corresponding author. Provincial Medical Genetics Program, Department of Medical Genetics, Children's and Women's Health Centre of BC, 4500 Oak St, Rm C234, Vancouver, British Columbia, Canada V6H 3N1. Tel.: +604 875 2157; Fax: +604 875 2376; E-mail: boerkoel@interchange.ubc.ca

¹⁰Present address: Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan

¹¹These authors contributed equally to this work

Received: 23 April 2007; accepted: 19 September 2007; published online: 18 October 2007

in vivo and suggests that SCAN1 arises from the recessive neomorphic mutation H493R. This is a novel mechanism for disease since neomorphic mutations are generally dominant.

The EMBO Journal (2007) 26, 4732–4743. doi:10.1038/sj.emboj.7601885; Published online 18 October 2007

Subject Categories: genome stability & dynamics; molecular biology of disease

Keywords: camptothecin; neurodegeneration; SCAN1; Tdp1; topoisomerase I

Introduction

DNA topoisomerases, glycosylases, methyltransferases, and recombinases act via formation of a transient covalent intermediate with DNA. When these DNA-processing enzymes become covalently trapped on the DNA, they cause a particularly harmful kind of DNA damage. The repair pathways for these types of lesions are of great interest because they influence the effectiveness of widely used antibacterial and antitumor drugs that act by stabilizing such covalent complexes (Connelly and Leach, 2004).

Inherited defects of DNA repair are associated with a predisposition to cancer and neurological abnormalities (Friedberg *et al*, 2006). To our knowledge, spinocerebellar ataxia with axonal neuropathy (SCAN1) is the first example of a human genetic disorder that results from a failure to repair DNA–protein covalent complexes. More importantly, the mutant protein responsible for the disease becomes itself covalently trapped on the DNA.

SCAN1 is an autosomal recessive disorder characterized by ataxia, cerebellar atrophy, and peripheral neuropathy (Takashima *et al*, 2002). The patients are usually wheelchair bound by early adulthood but retain normal cognitive function suggesting that the disease arises from degeneration or impairment of specific neurons (Takashima *et al*, 2002). SCAN1 has been associated with the *TDP1* 1478A>G mutation, which encodes the missense change H493R that disrupts the active site of tyrosyl-DNA phosphodiesterase 1 (Tdp1) (Interthal *et al*, 2001, 2005b; Takashima *et al*, 2002).

Tdp1 catalyzes the hydrolysis of the phosphodiester bond between a DNA 3' end and a tyrosine residue, a linkage specific to the enzyme–DNA covalent complex formed when a type IB DNA topoisomerase cleaves DNA (Yang *et al*, 1996). Topoisomerase I (Topo I) becomes covalently trapped in a dead-end complex on the DNA when it fails to religate the DNA after cleavage near endogenous lesions (nicks, gaps, or abasic sites) (Pommier, 2004). Tdp1 participates in the repair of Topo I–DNA complexes as a member of the mammalian DNA single-strand break repair complex (Pouliot *et al*, 2001; El-Khamisy *et al*, 2005; Interthal *et al*, 2005b).




Figure 2 Comparative phenotypic and histopathological evaluation of the *Tdp1*^{+/+} and *Tdp1*^{-/-} mice at P0 (A–I) and P270 (J–S). *P0 mice*: Hematoxylin and eosin (H&E) staining of cortex (A, B), cerebellar vermis (C, D), spinal cord (E, F), and dorsal root ganglion (G, H). Note the comparability of the external granular cell (EGL), molecular (ML), and internal granular cell layers (IGL) as well as the Purkinje cell number (PC). (I) Comparison of the body weights and lengths and brain weights of *Tdp1*^{+/+}, *Tdp1*^{+/-}, and *Tdp1*^{-/-} littermates. *P270 mice*: H&E staining of cortex (J, K), cerebellar vermis (L, M), spinal cord (N, O), and dorsal root ganglia (P, Q). The cortical layers are labeled in panels J and K and the cerebellar molecular (ML) and granular cell (GL) layers in panels L and M. The insets in panels N and O are higher magnifications of the dorsal (upper) and ventral (lower) horns. (R) Comparison of male and female body weights. (S) Comparison of the peripheral nerve electrophysiology of *Tdp1*^{+/+} and *Tdp1*^{-/-} littermates. Scale bar = 50 μ m.

Tdp1^{+/-} parents produced all genotypic classes in Mendelian ratios. Thus, in contrast to *Drosophila* (Dunlop *et al*, 2004) in which deficiency of glaikit, the *Tdp1* homolog, causes defective embryonic neurogenesis and embryonic lethality, *Tdp1*-deficient mice did not exhibit embryonic or neonatal lethality.

At birth, the *Tdp1*^{-/-} mice had body weights and lengths, brain weights and histopathology comparable to *Tdp1*^{+/+} mice (Figure 2A–I). This phenotype correlates with that of SCAN1 patients who had normal growth and motor, language, social and intellectual development throughout childhood (Takashima *et al*, 2002). However, in contrast to the SCAN1 patients who develop clinical symptoms in their

second decade of life (Takashima *et al*, 2002), the *Tdp1*^{-/-} mice examined at 270 days by histopathology and peripheral nerve electrophysiology did not show abnormalities (Figure 2J–S) and those analyzed at 14–17 months did not exhibit behavioral or other abnormalities. Thus, we propose that the *Tdp1*^{-/-} mice are able to repair endogenous levels of Topo I–DNA complexes by alternate DNA-repair pathways.

Alternative pathways for the repair of Topo I–DNA covalent complexes

In *Saccharomyces cerevisiae*, the two best-studied alternative pathways for repairing stalled Topo I are those mediated by

the structure-specific endonucleases Rad1/Rad10 and Mus81/Mms4 (Liu *et al*, 2002; Vance and Wilson, 2002), which correspond to mammalian XPF/ERCC1 and Mus81/Eme1, respectively (Matsunaga *et al*, 1995; Brookman *et al*, 1996; Ciccia *et al*, 2003; Ogrunc and Sancar, 2003). By *in situ* hybridization and RT-PCR across a spectrum of *Tdp1*^{+/+} mouse tissues, Xpf, Ercc1, and Mus81 were expressed at each time point investigated, whereas Eme1 generally had much lower neural expression except in the developing cerebellum (Supplementary Figures 1 and 2). Notably, Eme1 was expressed in non-neural tissues such as the thymus, heart, intestine, liver, skin, vertebrae, teeth, and testes (Supplementary Figure 1M, N). We observed a similar lack of neural expression of Eme1 in the adult human brain by RT-PCR (Supplementary Figure 2T) and northern analyses (data not shown). The mRNAs encoding these endonucleases (Supplementary Figure 2U) as well as the mRNAs encoding the base excision repair enzymes *Apex1* and *Apex2* (data not shown) were not increased in *Tdp1*^{-/-} brain tissue. Thus, although not upregulated in *Tdp1*^{-/-} tissue, the XPF/ERCC1 pathway may function as one alternative pathway for repair of Topo I-DNA complexes in the absence of Tdp1 (Vance and Wilson, 2002), and the low or absent Eme1 expression in the majority of neuronal tissues might contribute to the neuronal specificity of SCAN1.

***Tdp1* is expressed in the nervous system of mice and humans**

To test whether variation in expression across species accounted for the difference in phenotype between *Tdp1*^{-/-} mice and SCAN1 patients, we compared the expression of Tdp1 in mice and humans. By northern blot analysis, human Tdp1 mRNA was present in all analyzed adult tissues (Supplementary Figure 3A) and in all tested areas of the central nervous system (Supplementary Figure 3B). Similarly, mouse Tdp1 mRNA was expressed in all analyzed adult tissues (Supplementary Figure 3C) and in the brain from embryonic day (E) 9.5 through adulthood (Supplementary Figure 3D).

In the human brain, Tdp1 was highly expressed in neurons from 10 gestational weeks (GW) through 16 years of age and at very low levels in glia (Figure 3A–C). Similar to the *Drosophila glaikit* protein (Dunlop *et al*, 2000), human Tdp1 was expressed in subependymal neural progenitors and cultured neurospheres (Figure 3A and Supplementary Figure 4). Cerebellar, granule and Purkinje cells (Figure 3D–F) and neurons of the dentate nucleus (Figure 3G), spinal cord (Figure 3H), and dorsal root ganglia (DRG) (Figure 3I), the neurons putatively affected by SCAN1 (Takashima *et al*, 2002), also expressed Tdp1. Similar to the *glaikit* protein in *Drosophila*, the Tdp1 protein was prominently expressed in the cytoplasm of some neurons (Figure 3F–H), a poorly understood finding; however, in contrast to human Tdp1, *glaikit* is not thought to participate in DNA repair but in localization of membrane proteins (Dunlop *et al*, 2000, 2004). Antiserum nonspecificity does not account for this staining pattern because we obtained the same results with two independently produced antisera, and the preimmune serum did not recognize either a nuclear or a cytoplasmic antigen (Figure 3J–K). Moreover, the antisera recognized a 70 kDa protein in mouse *Tdp1*^{-/-} fibroblasts transfected with a human Tdp1 expression plasmid but not in untransfected

Tdp1^{-/-} fibroblasts (Figure 3L), and competitive inhibition with recombinant Tdp1 protein blocked interaction of the anti-human (Figure 3M) and anti-mouse sera with Tdp1 (data not shown). Although we observed this staining pattern in the tissues from several individuals, this finding could be an artefact of tissue fixation since in our experience Tdp1 readily diffuses out of the nucleus of dying human and mouse cells. Alternatively, this might suggest either cytoplasmic sequestration or a cytoplasmic function for Tdp1 in humans but not in mice.

With the exception of the cytoplasmic localization, the mouse brain showed a similar expression pattern for the Tdp1 RNA and protein (Figure 4). This suggested to us that SCAN1 arises either from loss of a human-specific function as reflected by the differences in protein localization or from a novel function of Tdp1 created by the H493R mutation.

***Tdp1*^{-/-} mice, neurospheres, and embryonic fibroblasts are CPT hypersensitive**

Like cells from the SCAN1 patients (El-Khamisy *et al*, 2005; Interthal *et al*, 2005b), *Tdp1*^{-/-} mouse embryonic fibroblasts (MEFs, Supplementary Figure 6A, D–G) and neurospheres (Figure 5A) were hypersensitive to CPT. Therefore, we hypothesized that the *Tdp1*^{-/-} mice, and perhaps in particular the nervous system of these mice, would have increased sensitivity to CPT and that CPT treatment might induce a SCAN1-like phenotype. Intraperitoneal administration of the Topo I poison CPT-11 as a single (80 mg/kg) or a weekly (40 mg/kg, for 20 weeks) dose elicited no detectable phenotype in *Tdp1*^{-/-} or *Tdp1*^{+/+} mice aged 70–210 days (Figure 5B). But five consecutive daily doses of CPT-11 (40 mg/kg/day) or of topotecan (1.6 or 4.8 mg/kg/day) were toxic to *Tdp1*^{-/-} mice ranging in age from 70 to 80 days (Figure 5B). Although the same age *Tdp1*^{+/+} mice were unaffected, the *Tdp1*^{-/-} mice developed weakness and diarrhea and expired within 2 days after completion of CPT-11 or topotecan administration. By histopathology and immunohistochemistry, there was extensive necrosis in the more slowly proliferating intestinal, renal, and hepatic tissues (Figure 5C–J), and extensive apoptosis and marked tissue loss in the more rapidly proliferating lymphoid and hematopoietic tissues (Figure 5K–R). The induction of apoptosis in these rapidly proliferating tissues indicates that Tdp1, as expected, is involved in the repair of Topo I-associated DNA double-strand breaks that are generated when the replication machinery collides with CPT-trapped Topo I. The treated *Tdp1*^{-/-} mice also had electrophysiological changes, prolonged distal latencies, and reduced compound muscle action potentials (Supplementary Figure 5A), changes typically seen in acute illness but different from those of the SCAN1 patients (Takashima *et al*, 2002). Whether treated with CPT-11 or topotecan, *Tdp1*^{-/-} mice did not exhibit ataxia or have detectable atrophy or apoptosis in the cerebrum, cerebellum, spinal cord, DRG, or peripheral nerve by histological, immunohistochemical, TUNEL, or ultrastructural analyses (Supplementary Figure 5B–U). In addition, the *Tdp1*^{-/-} glia and neurons differentiated from neurospheres (Supplementary Figure 5V, W) or cultured *Tdp1*^{-/-} cortical neurons (data not shown) failed to exhibit cell death or apoptosis at CPT doses that impaired neurosphere proliferation.




Figure 3 Immunohistochemical analysis of Tdp1 protein expression in the human brain. (A) Tdp1 expression in the cerebrum of a human 10 gestational week (GW) brain. Cells adjoining the ventricle (V), and in the subventricular zone (SVZ), intermediate zone (IMZ), and cortical plate (CP) express Tdp1. (B, C) Tdp1 expression in layer two of the cortex from a 40 GW and a 16-year brain. (D–F) Tdp1 expression in the cerebella from a 22 GW, a 9-month and a 4-year brain. Note the staining in the external granular cell layer (EGL), Purkinje cells (PC), and internal granular cell layer (IGL). (G) Tdp1 expression in a 19-year dentate gyrus. (H, I) Tdp1 expression in spinal cord anterior horn cells (AHC) and a dorsal root ganglion of a 10-year old, respectively. (J–M) Specificity of the immune serum is shown by absence of staining of the spinal cord (J) and dorsal root ganglion (K) from a 10-year old with preimmune serum and also by absence of antigen recognition in mouse *Tdp1*^{-/-} mouse embryonic fibroblasts compared to *Tdp1*^{-/-} fibroblasts transfected with a human Tdp1 expression construct (*Tdp1*^{-/-} + *pCMV5-Tdp1*) (L), and competitive inhibition of the antiserum by recombinant human Tdp1 (M). Scale bar = 50 μm.


In summary, these results confirm that the CPT hypersensitivity of SCAN1 lymphoblastoid cells is likely arising because of deficient Tdp1 activity. However, they also highlight

the possibility that the neuropathology of SCAN1 may not be caused solely by deficient Tdp1 activity because accentuation of the formation of Topo I–DNA complexes with the admin-


Figure 4 *In situ* hybridization and immunohistochemistry showing the spatial and temporal expression of mouse Tdp1 mRNA and protein, respectively. Localization of the Tdp1 mRNA in P1 (A–D), P10 (E–H), and adult (I–L) mice. (A, E, I) Expression of Tdp1 mRNA in a midline sagittal section from a P1, P10, and adult mouse or brain, respectively. Note that Tdp1 is expressed throughout the cortex (Cx), cerebellum (Cb), spinal cord (SC), and dorsal root ganglia (DRG) as well as most other organs including the skin, thymus (Th), heart, lungs, liver, and intestines. (B, F, J) Expression of Tdp1 mRNA in the cortex (Cx) and hippocampus (Hip) of a P1, P10, and adult brain, respectively. (C, G, K) Expression of Tdp1 mRNA in a coronal section of a P1, P10, and adult cervical spinal cord, respectively. The highest expression is in the dorsal horns (DH) and the ventral horns (VH). (D, H, L) Expression of Tdp1 mRNA in a cross-section of a P1, P10, and adult dorsal root ganglion, respectively. (M–O) Serial sections from the P1 mouse hybridized with a sense probe for Tdp1 showing the specificity of the hybridization for the antisense probe used in panels A–L. Scale bar = 1 cm (A, E, I, M), 0.5 mm (B, C, F, G, J, K, N, O), 0.2 mm (D, H, L). Localization of the Tdp1 protein in the P0 and the P270 CNS (P–AA). (P) P0 cortex and hippocampus, (Q) P0 layer II cortical neurons, (R) P270 cortex, (S) P270 layer II cortical neurons, (T) P0 cerebellum, (U) P270 cerebellum, (V) P270 dentate nucleus, (W) P270 spinal cord. Nonspecific staining of the P0 cortex (X), P270 cortex (Y), P0 cerebellum (Z), and P270 cerebellum (AA). Scale bar = 0.5 mm (P, R, T, U, Y, Z, AA, BB), 0.2 mm (X), 50 μm (Q, S, and all insets). Abbreviations: EGL, external granular layer; PC, Purkinje cell; ML, molecular layer; VH, ventral horn; VHC, ventral horn cell; DH, dorsal horn.

istration of Topo I inhibitors did not cause SCAN1-like neural dysfunction. Rather, nonproliferating *Tdp1*^{-/-} neural cells in culture and *in vivo* did not show acute toxicity to Topo I-DNA complexes, whereas proliferating *Tdp1*^{-/-} cells *in vivo* were quite sensitive to the toxicity of Topo I-DNA complexes (Figure 5 and Supplementary Figure 5). The resistance of nonproliferating neural cells to topotecan and CPT-11 cannot


be ascribed to the failure of these drugs to penetrate the blood-brain barrier since topotecan penetration of the blood-brain barrier is well established in rodents (El-Gizawy and Hedaya, 1999; Zhuang *et al*, 2006). In addition, the DRG, which resides outside of the blood-brain barrier (Arvidson, 1979), did not exhibit histopathological changes (Supplementary Figure 5).



Immunohistochemistry



Preimmune



The resistance of nonproliferating neural cells to CPT might suggest that alternative pathways are able to repair low levels of Topo I–DNA complexes. The existence of such alternative pathways is supported by the observation of Xpf induction in lung tumors commonly resistant to camptothecin (Sestili *et al*, 2006) and by the increased levels of homologous recombination in SCAN1 patient lymphoblastoid cells (El-Khamisy *et al*, 2005). Additionally, we have evidence for the existence of an endonuclease-dependent repair pathway for stalled Topo I (J Leppard, H Interthal, and J Champoux, unpublished).

***Tdp1*^{-/-} mice and embryonic fibroblasts are bleomycin but not etoposide hypersensitive**

SCAN1 cells are also deficient in processing of DNA phosphoglycolate 3' ends (Inamdar *et al*, 2002; Zhou *et al*, 2005). Therefore, we hypothesized that the *Tdp1*^{-/-} cells and mice would have increased sensitivity to bleomycin. By the comet assay, *Tdp1*^{-/-} MEFs were hypersensitive to bleomycin (Supplementary Figure 6B), and with intraperitoneal administration of the bleomycin for 10 consecutive days (10 mg/kg/day), *Tdp1*^{-/-} mice developed weakness and expired within 4 days following treatment. Histopathology and immunohistochemistry showed extensive apoptosis and marked tissue loss in the more rapidly proliferating lymphoid and hematopoietic tissues (Supplementary Figure 6H–K). The treated *Tdp1*^{-/-} mice did not exhibit ataxia or electrophysiological changes typical of SCAN1 or have detectable atrophy or apoptosis in the cerebrum, cerebellum, spinal cord, or DRG peripheral nerve (Supplementary Figure 6L–O and data not shown).

Tdp1 is also proposed to participate in the repair of DNA double-strand breaks resulting from stalling of Topoisomerase II (Topo II) (Barthelmes *et al*, 2004; Nitiss *et al*, 2006). If Tdp1 played a key role in this repair process, then *Tdp1*^{-/-} cells and mice might have increased sensitivity to etoposide, a Topo II inhibitor (Liu, 1989). However, consistent with the studies of lymphoblastoid cells from SCAN1 patients (Interthal *et al*, 2005b), neither *Tdp1*^{-/-} MEFs nor mice showed increased sensitivity to etoposide (Supplementary Figure 6C, P–W). Both *Tdp1*^{+/+} and *Tdp1*^{-/-} mice became ill and died 2 or 3 days after 5 consecutive days of 30 or 40 mg/kg/day of etoposide, and both were equally symptom free 60 days after 5 days of 20 mg/kg/day of etoposide. The *Tdp1*^{+/+} and *Tdp1*^{-/-} mice did not have detectable pathological differences by histological, immunohistochemical, or TUNEL analyses (Supplementary Figure 6P–W and data not shown).

These *in vivo* and cell culture studies confirm the participation of Tdp1 in the repair of DNA phosphoglycolate 3' ends but not in the repair of Topo II–DNA complexes. Moreover, the absence of an SCAN1-like phenotype in the treated mice again highlights the possibility that SCAN1 might not arise solely from deficient Tdp1 activity.

CPT treatment of cells expressing Tdp1 H493R causes the accumulation of H493R–DNA complexes and the accumulation of DNA strand breaks

The above observations suggested that SCAN1 is caused by a novel and distinct function of Tdp1 created by the SCAN1 point mutation. Previously, Interthal *et al* (2005a, b) hypothesized that SCAN1 might not only arise from the 25-fold reduction in activity caused by the H493R change, but also


from the accumulation of the Tdp1 H493R–DNA covalent reaction intermediate which has a half-life of ~13 min. The removal of H493R Tdp1 from the DNA by wild-type Tdp1 explains the recessive nature of SCAN1 (Interthal *et al*, 2005a, b). To test whether Tdp1 H493R becomes trapped on the genomic DNA *in vivo* in response to CPT treatment, we analyzed telomerase-immortalized skin fibroblasts from unaffected controls and SCAN1 patients using a modified *in vivo* complex of enzyme (ICE) assay (Subramanian *et al*, 1995). CPT-treated fibroblasts from both sources accumulated the Topo I–DNA covalent intermediate as expected, but only SCAN1 cells accumulated a covalent Tdp1–DNA intermediate (Figure 6A). Based on alkaline comet assay analyses and accumulation of γ H2AX, CPT-treated *Tdp1*^{-/-} MEFs expressing the human H493R Tdp1 protein accumulated DNA strand breaks more rapidly and to a higher level than CPT-treated *Tdp1*^{-/-} MEFs transfected with the control expression plasmid (Figure 6B and Supplemental Figure 7). In contrast, reduced accumulation of DNA strand breaks was evident upon expressing the wild-type Tdp1 protein (Figure 6B and Supplemental Figure 7).

These data show that the human H493R Tdp1 has an enzymatic activity *in vivo* that is qualitatively different from the Tdp1 activity in *Tdp1*^{-/-} cells or *Tdp1*^{-/-} cells complemented with wild-type Tdp1. This defines Tdp1 H493R as a neomorphic mutation. Moreover, the covalent stalling of H493R Tdp1 on the DNA in CPT-treated SCAN1 cells provides direct evidence that human Tdp1 removes CPT-trapped Topo I from the DNA *in vivo*.

Model for the repair of covalent Topo I–DNA complexes and the molecular mechanism of SCAN1

We previously had hypothesized that SCAN1 arises from cell death or cellular malfunction secondary to the accumulation of Topo I–DNA complexes; however, our data here suggest that Tdp1–DNA intermediates arising from antecedent Topo I–DNA complexes may be the underlying basis for the disease (Figure 6C). Although treatment of *Tdp1*^{-/-} mice with Topo I inhibitors or bleomycin might have recapitulated the SCAN1 phenotype if sufficient DNA damage was able to accumulate, *Tdp1*^{-/-} mice treated with either high or low doses of drug did not develop an SCAN1-like phenotype. This suggests that the resultant DNA complexes are not the initiating lesions; however, it seems more likely that for the high doses, the drug-induced damage greatly exceeded the repair capacity of the mice and therefore failed to mimic the low level of naturally occurring lesions that accumulate in SCAN1 patients. And for low doses of drug, redundant pathways effectively repaired the DNA damage. Therefore, we hypothesize that the prolonged half-life of the H493R Tdp1–DNA complexes and the increased level of DNA damage in neuronal cells is the origin of the cellular malfunction underlying SCAN1. Such an increase in DNA damage in neuronal cells could arise from decreased efficiency Tdp1–DNA adduct removal since some DNA repair pathways are attenuated in terminally differentiated cells (Nouspikel and Hanawalt, 2002). Testing this model requires analysis of another mouse model solely expressing the mutant H493R Tdp1 rather than the loss of function mutation described here.

Relevant to the treatment of cancer, the absence of detectable acute effects of CPT and bleomycin treatment on the murine nervous system suggests that nonproliferating cells of



Histological phenotype following CPT-11 40 mg/kg/day for 5 days




Figure 5 Analysis of CPT-11-treated and untreated *Tdp1*^{+/+} and *Tdp1*^{-/-} cells and mice. (A) CPT sensitivity of *Tdp1*^{+/+} and *Tdp1*^{-/-} neurosphere cells following 72 h of incubation with camptothecin (CPT) at the indicated concentrations. (B) CPT-11 and topotecan treatment protocols and outcomes for *Tdp1*^{+/+} and *Tdp1*^{-/-} mice. Note that only mice treated repetitively at short intervals developed a phenotype; this suggests a high level of redundancy for the removal of stalled Topo I. (C–R) Histopathology and TUNEL staining of liver and spleen derived from *Tdp1*^{+/+} and *Tdp1*^{-/-} mice treated with 40 mg/kg of CPT-11 for 5 days. Note the extensive vacuolization (F) but paucity of TUNEL-positive cells (J) in the liver of *Tdp1*^{-/-} mice suggesting necrotic cell death. In contrast, the lymphoid and hematopoietic tissues such as the spleen showed marked loss of tissue (M versus N) with a large number of TUNEL-positive cells (Q versus R) suggesting cell death by apoptosis.

the nervous system are insensitive to Topo I–DNA complexes and 3' phosphoglycolate–DNA damage. Thus, in contrast to the accentuation of demyelinating neuropathies by some chemotherapies (Weimer and Podwall, 2006), short-term administration of these chemotherapeutic agents is unlikely to induce neurological disease even in the absence of *Tdp1*. Additionally, our observations suggest that *Tdp1* is also a

reasonable chemotherapeutic target as long as the formation and consequences of *Tdp1*–DNA complexes in non-neoplastic tissues are carefully assessed.

In summary, SCAN1 is the first example of a human genetic disease that results from a failure to repair DNA–protein covalent complexes. SCAN1 likely arises not only from a quantitative change in *Tdp1* activity but also from a




Figure 6 Stalling of H493R Tdp1 on DNA and a model for the causation of SCAN1. (A) *In vitro* complex of enzyme assay showing that treatment of unaffected and SCAN1 patient skin fibroblasts with camptothecin (CPT) causes formation of a covalent Tdp1-DNA complex in the SCAN1 fibroblasts but not in unaffected fibroblasts (upper panel). The expected covalent Topo I-DNA complex (middle panel) and the relative abundance of each protein (lower panel) are also shown. (B) Alkaline comet assay showing increased CPT induction of DNA strand breaks in *Tdp1*^{-/-} MEFs expressing H493R Tdp1 (*pcDNA3.1(-)*·*TDP1*^{1478A>G}) and reduced induction of DNA breaks in *Tdp1*^{-/-} MEFs expressing wild-type Tdp1 (*pcDNA3.1(-)*·*TDP1*^{WT}). The comet moments were measured following treatment with 1 μM CPT for 1 h and recovery in CPT-free medium for the indicated times. The comet moment of *Tdp1*^{-/-} MEFs transfected with only the expression vector (*pcDNA3.1(-)*) was significantly different from *TDP1*^{WT} and *TDP1*^{1478A>G} (***P* < 0.001). The expression of human wild type and H493R Tdp1 was detected in the transfected cells by western blot (data not shown) and RT-PCR followed by *Bsa*I digestion of the products (lower panel) as previously described (Takashima *et al*, 2002). Lane 1: molecular weight markers; lane 2: *Tdp1*^{-/-} MEFs transfected with plasmid *pcDNA3.1(-)*, the empty vector; lane 3: *Tdp1*^{-/-} MEFs transfected with plasmid *pcDNA3.1(-)*·*TDP1*^{WT}, the expression vector for wild-type human TDP1 cDNA; lane 4: *Tdp1*^{-/-} MEFs transfected with plasmid *pcDNA3.1(-)*·*TDP1*^{1478A>G}, the expression vector for human H493R Tdp1 cDNA. Note that the 1478A>G mutation creates a *Bsa*I restriction site. (C) Potential model for the molecular basis of SCAN1. DNA breaks with blocked 3' ends (e.g., Topo I or phosphoglycolate) undergo Tdp1-facilitated DNA repair via both DNA single-strand break repair (SSBR) and double-strand break repair (DSBR) mechanisms. With loss of functional Tdp1 (*Tdp1*^{-/-}), there is sufficient redundant activity for adequate DNA repair by alternative pathways (e.g. endonuclease-dependent pathways) unless the system is further stressed as by administration of CPT or bleomycin. In contrast, when Tdp1 carries the H493R mutation, it not only has a quantitative reduction in overall activity, but also a qualitative change resulting in accumulation of Tdp1-DNA complexes. These complexes are efficiently removed from the DNA by wild-type Tdp1 in all tissues of heterozygotes, whereas they are only removed in replicating cells of homozygotes by alternative DNA strand break repair mechanisms. According to this model, the transcriptional interference and/or apoptosis resulting from the Tdp1-DNA complexes in nondividing neurons causes SCAN1 via neurodegeneration.

qualitative change that renders the enzyme different from wild-type Tdp1 causing it to become covalently trapped on the DNA. Furthermore, since the previously described disease-causing neomorphic mutations are dominant (Antonarakis *et al*, 2001; Beaudet *et al*, 2001), the recessive nature of the neomorphic Tdp1 H493R mutation (Interthal *et al*, 2005a,b) defines a novel mechanism for human disease.

Materials and methods

Human subjects

Patients gave informed consent approved by the Institutional Review Board of Baylor College of Medicine (H-9669, Houston, TX, USA) and the University of British Columbia (C06-0283, Vancouver, BC, Canada). The clinical data were collected from questionnaires completed by the referring primary care physician and from medical records and summaries provided by that physician.

Animal subjects

Mice used in this study were housed, bred, and killed in accordance with accepted ethical guidelines. These procedures were approved by the Institutional Review Board of Baylor College of Medicine (Houston, TX, USA, IRB protocol: AN-2983), the University of British Columbia (Vancouver, BC, Canada, Animal Care Certificate: A06-0257), and Kagoshima University (Kagoshima, Japan).

Transgenic mice

We purchased the gene trap embryonic stem (ES) cell line XD105 from BayGenomics (<http://baygenomics.ucsf.edu/>). XD105 was generated by integration of *pGTILxf* into intron 11 of *Tdp1*. This cell line was injected into albino C57 blastocysts that were then implanted into pseudopregnant mothers. The resulting chimeric mice were bred to 129/SvEv females to generate founders. The progeny from these heterozygous founders were used for all subsequent analyses. Mice were genotyped by PCR of genomic DNA using a common forward primer in intron 11 and a reverse primer in either intron 11 or in *pGTILxf* (Supplementary Table 1) and data not shown. The intron 11 primer pair detects the wild-type allele but not the trapped allele, and the intron 11 forward primer with the *pGTILxf* reverse primer detects the mutant allele but not the wild-type allele. The PCR was carried out using HotMasterMix (Eppendorf) with 50 ng of genomic DNA and 10 pmol of each primer. After initial denaturation at 94°C for 2 min, amplification was performed for 40 cycles with denaturation at 94°C for 20 s, annealing at 55°C for 10 s, extension at 65°C for 90 s.

To determine if the gene trap allowed expression of full-length *Tdp1* mRNA by splicing around the gene trap, we performed RT-PCR on brain RNA extracted from *Tdp1*^{-/-} mice (Figure 1B). The RT-PCR primers 5' of the trap reside in exon 2, and the primers 3' of the trap reside in exons 12 and 16, respectively (Supplementary Table 1). The RT-PCR amplification was performed as described below. To determine if the gene trap allowed expression of aberrantly spliced mRNA, we performed RT-PCR using primers residing in exons 9 and 14 (Supplementary Table 1).

Bleomycin, CPT-11, etoposide, and topotecan treatment of mice

Bleomycin (Bristol-Myers Squibb, Montreal, Canada), CPT-11 (Yakult Honsha Co., Tokyo, Japan), etoposide (Novapharm, Toronto, Canada), or topotecan (LKT laboratories, Inc.) were diluted with 5% Dextrose solution prior to intraperitoneal injection. Drug or PBS was given to five wild-type and five *Tdp1*^{-/-} mice according to the dosages and administration schedules indicated in the Results and Figure 5B. The mice were evaluated by electrophysiology (Supplementary data) 2 days after the last dose of CPT-11, topotecan, or bleomycin.

Comet assay

For Figure 6 and Supplementary Figure 6, the MEFs were treated with 1 μM CPT, 12.5 μg/ml bleomycin, or 12.5 μg/ml etoposide for 60 min. For Figure 6, the CPT containing medium was then replaced

with fresh medium and the cells were allowed to recover for the indicated times. The MEFs were then removed from the plates with trypsin, washed with medium, resuspended in LMAgarose, and layered on agarose-coated slides cooling on ice.

Alkali comet assay (Singh *et al*, 1988). For CPT- or bleomycin-treated MEFs, the slides were immersed in lysis solution (2.5 M NaCl, 100 mM EDTA, 10 mM Trizma base, 1% Triton X-100, 10% dimethyl sulfoxide; pH 10) at 4°C for 1 h. After a rinse in deionized water, slides were immersed in a 4°C alkaline solution (50 mM NaOH, 1 mM EDTA, 1% dimethyl sulfoxide; pH > 13) for 25 min. Electrophoresis was carried out at a constant voltage of 25 V for 25 min at 4°C. After electrophoresis, slides were neutralized in 0.4 M Tris-HCl pH 7.5.

Neutral comet assay (Olive *et al*, 1992). For etoposide-treated MEFs, the slides were immersed in lysis solution (50 mM EDTA, 0.5% SDS; pH 7.5) at 4°C for 1 h. After a rinse in deionized water, slides were immersed in 4°C TBE for 25 min. Electrophoresis was carried out at a constant voltage of 25 V for 25 min at 4°C.

After electrophoresis for both methods, slides were dehydrated in ice-cold 70% ethanol for 5 min and air-dried. DNA was stained with Sybr Green I. A total of 100 comets were scored for each sample using CASP (Konca *et al*, 2003) and statistically significant differences in the distribution of comet moments were determined using the Student *t*-test.

Anti-Tdp1 serum production

An anti-human Tdp1 serum was generated in rabbits against Tdp1 amino acids 1–152. An anti-mouse Tdp1 serum was generated in guinea pigs against the full-length protein (amino acids 1–608). Both antigens were produced in *Escherichia coli* with the pET28a expression system (Novagen). Neither antigen displayed homology to other human proteins by BLASTp. The specificity of each antiserum was confirmed by the absence of crossreactivity with recombinant Tdp1 expressed in *Tdp1*^{-/-} MEFs and by competitive blocking with recombinant human or mouse Tdp1, respectively.

Immunohistochemistry and histopathology

Human and mouse brains were fixed by immersion in 10% buffered formalin or 4% PFA in PBS. The brain tissue was processed, embedded in paraffin, and cut into 8 mm sections according to standard protocols (Deguchi *et al*, 2003). Immunohistochemistry was carried out as previously described (Kilic *et al*, 2005). We used the polyclonal rabbit anti-human Tdp1 at a dilution of 1:50 and the polyclonal guinea pig anti-mouse Tdp1 at a dilution of 1:50. TUNEL detection of apoptotic cells was carried out using the ApopTag Peroxidase *In Situ* Apoptosis Detection Kit (Chemicon, S7100) and the tissue was counterstained with 1% methyl green.

Modified ICE assay (Subramanian *et al*, 1995)

Briefly, two confluent 15 cm Petridishes of telomerase immortalized SCAN1 or control human fibroblasts were treated with 20 μM CPT for 1 h. Cells were lysed in 0.8% SDS in TE and the genomic DNA was sheared with a syringe. Small aliquots of the whole cell extracts were mixed with SDS loading buffer for later analysis. The remaining cell lysates were diluted four-fold with 1% *N*-lauroyl-sarcosine and the extracts were layered onto a CsCl cushion (1.5 g/cc). After ultracentrifugation, the pellet fraction was treated with micrococcal nuclease to remove the majority of the DNA bound to the proteins. Samples were mixed with SDS sample buffer and subjected to SDS-PAGE and western blotting.

Tdp1 activity assay with mouse neurosphere cell extracts

Exponentially growing neurospheres were harvested by centrifugation, washed twice in PBS, and resuspended to 8 × 10⁷ cells/ml in lysis buffer (10 mM Tris-HCl (pH 7.5), 50 mM KCl, 2 mM MgCl₂, 1% Triton X-100, 15 mM DTT, 0.2 mg/ml PMSF, 1/1000 volume of protease inhibitor mixes Pic-D (5 mg/ml Pepstatin A, 1 mg/ml chymostatin in DMSO), and Pic-W (208 mg/ml benzamidin, 5 mg/ml aprotinin, and 1 mg/ml leupeptin in H₂O)). The cells were lysed by vortexing for 1 min and the cell extracts were clarified by centrifugation.

Cell extracts were first diluted 1:2 with 2 × reaction buffer (200 mM KCl, 40 mM Tris-HCl (pH 7.5), 40 mM EDTA, 2 mM DTT) and then 10-fold serially diluted in reaction buffer. For the

experiment shown in Figure 1D, 10 μ l of the extract dilutions was added to 5 μ l of reaction buffer containing 0.01 pmol of 32 P-5' end-labeled substrate 12-Y (a 12-mer DNA oligonucleotide with a 3' phosphotyrosine (Interthal *et al*, 2005b)) and the reactions were incubated at 37°C for 30 min and stopped with an equal volume of formamide loading dye. Assays were analyzed on a 15% sequencing gel. Image retrieval and quantitation were carried out using a PhosphorImager and ImageQuant software (Amersham Biosciences).

Supplementary data

Supplementary data are available at *The EMBO Journal* Online (<http://www.embojournal.org>).

Acknowledgements

We thank Millan Patel, Leah Elizondo, J Marietta Clewing, and Kensuke Shiga for critical reviews of this manuscript. We thank

Barbara A Antalfy and Pauline Grennan for preparation of tissue; Monica J Justice, Darlene Skapura, and Wei Yu for mouse tissue; and Akiko Yoshimura and Yuko Shirahama for technical assistance. This work was supported in part by grants from the National Institute of Diabetes, Digestive, and Kidney Diseases, NIH (CFB, DLA), the New Development Award, Microscopy, and Administrative Cores of the Mental Retardation and Developmental Disabilities Research Center at Baylor College of Medicine (CFB, DLA), the National Ataxia Foundation (CFB), the Burroughs Wellcome Foundation (CFB), the Nervous and Mental Disorders and Research Committee for Ataxic Disease of the Japanese Ministry of Health, Welfare and Labor (grant 17A-1, HT, KA), Frontier Science Research Center Program of Kagoshima University (HT), and the Ministry of Education, Culture, Sports, Science, and Technology of Japan (grant 19591001, HT) and by NIH Grant GM049156 (JJC). NHLBI's Programs for Genomic Applications supported the generation of insertion trap ES cells at BayGenomics (grant U01 HL66621).

References

- Antonarakis SE, Krawczak M, Cooper DN (2001) The nature and mechanisms of human gene mutation. In *The Metabolic & Molecular Bases of Inherited Disease*, Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B (eds), pp 343–377. New York: McGraw-Hill
- Arvidson B (1979) Distribution of intravenously injected protein tracers in peripheral ganglia of adult mice. *Exp Neurol* **63**: 388–410
- Barthelmes HU, Habermeyer M, Christensen MO, Mielke C, Interthal H, Pouliot JJ, Boege F, Marko D (2004) TDP1 overexpression in human cells counteracts DNA damage mediated by topoisomerases I and II. *J Biol Chem* **279**: 55618–55625
- Beaudet AL, Scriver CR, Sly WS, Valle D (2001) Genetics, biochemistry, and molecular bases of variant human phenotypes. In *The Metabolic & Molecular Bases of Inherited Disease*, Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B (eds), pp 3–45. New York: McGraw-Hill
- Brookman KW, Lamerdin JE, Thelen MP, Hwang M, Reardon JT, Sancar A, Zhou ZQ, Walter CA, Parris CN, Thompson LH (1996) ERCC4 (XPF) encodes a human nucleotide excision repair protein with eukaryotic recombination homologs. *Mol Cell Biol* **16**: 6553–6562
- Ciccio A, Constantinou A, West SC (2003) Identification and characterization of the human mus81-eme1 endonuclease. *J Biol Chem* **278**: 25172–25178
- Connelly JC, Leach DR (2004) Repair of DNA covalently linked to protein. *Mol Cell* **13**: 307–316
- D'Arpa P, Beardmore C, Liu LF (1990) Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. *Cancer Res* **50**: 6919–6924
- Deguchi K, Inoue K, Avila WE, Lopez-Terrada D, Antalfy BA, Quattrocchi CC, Sheldon M, Mikoshiba K, D'Arcangelo G, Armstrong DL (2003) Reelin and disabled-1 expression in developing and mature human cortical neurons. *J Neuropathol Exp Neurol* **62**: 676–684
- Dunlop J, Corominas M, Serras F (2000) The novel gene *glaiKit*, is expressed during neurogenesis in the *Drosophila melanogaster* embryo. *Mech Dev* **96**: 133–136
- Dunlop J, Morin X, Corominas M, Serras F, Tear G (2004) *GlaiKit* is essential for the formation of epithelial polarity and neuronal development. *Curr Biol* **14**: 2039–2045
- El-Gizawy SA, Hedaya MA (1999) Comparative brain tissue distribution of camptothecin and topotecan in the rat. *Cancer Chemother Pharmacol* **43**: 364–370
- El-Khamisy SF, Caldecott KW (2007) DNA single-strand break repair and spinocerebellar ataxia with axonal neuropathy-1. *Neuroscience* **145**: 1260–1266
- El-Khamisy SF, Saifi GM, Weinfeld M, Johansson F, Helleday T, Lupski JR, Caldecott KW (2005) Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. *Nature* **434**: 108–113
- Friedberg EC, Walker GC, Siede W, Wood RD, Schultz RA, Ellenberger T (2006) Disease States associated with defective biological responses to DNA damage. In *DNA Repair and Mutagenesis*, pp 863–1080. Washington: ASM Press
- Inamdar KV, Pouliot JJ, Zhou T, Lees-Miller SP, Rasouli-Nia A, Povirk LF (2002) Conversion of phosphoglycolate to phosphate termini on 3' overhangs of DNA double strand breaks by the human tyrosyl-DNA phosphodiesterase hTdp1. *J Biol Chem* **277**: 27162–27168
- Interthal H, Chen HJ, Champoux JJ (2005a) Human Tdp1 cleaves a broad spectrum of substrates, including phosphoamide linkages. *J Biol Chem* **280**: 36518–36528
- Interthal H, Chen HJ, Kehl-Fie TE, Zotzmann J, Leppard JB, Champoux JJ (2005b) SCAN1 mutant Tdp1 accumulates the enzyme-DNA intermediate and causes camptothecin hypersensitivity. *EMBO J* **24**: 2224–2233
- Interthal H, Pouliot JJ, Champoux JJ (2001) The tyrosyl-DNA phosphodiesterase Tdp1 is a member of the phospholipase D superfamily. *Proc Natl Acad Sci USA* **98**: 12009–12014
- Kilic SS, Donmez O, Sloan EA, Elizondo LI, Huang C, Andre JL, Bogdanovic R, Cockfield S, Cordeiro I, Deschenes G, Frund S, Kaitila I, Lama G, Lamfers P, Lucke T, Milford DV, Najera L, Rodrigo F, Saraiva JM, Schmidt B *et al.* (2005) Association of migraine-like headaches with Schimke immuno-osseous dysplasia. *Am J Med Genet A* **135**: 206–210
- Konca K, Lankoff A, Banasik A, Lisowska H, Kuszewski T, Gozdz S, Koza Z, Wojcik A (2003) A cross-platform public domain PC image-analysis program for the comet assay. *Mutat Res* **534**: 15–20
- Liu C, Pouliot JJ, Nash HA (2002) Repair of topoisomerase I covalent complexes in the absence of the tyrosyl-DNA phosphodiesterase Tdp1. *Proc Natl Acad Sci USA* **99**: 14970–14975
- Liu LF (1989) DNA topoisomerase poisons as antitumor drugs. *Annu Rev Biochem* **58**: 351–375
- Matsunaga T, Mu D, Park CH, Reardon JT, Sancar A (1995) Human DNA repair excision nuclease. Analysis of the roles of the subunits involved in dual incisions by using anti-XPG and anti-ERCC1 antibodies. *J Biol Chem* **270**: 20862–20869
- Miao ZH, Agama K, Sordet O, Povirk L, Kohn KW, Pommier Y (2006) Hereditary ataxia SCAN1 cells are defective for the repair of transcription-dependent topoisomerase I cleavage complexes. *DNA Repair (Amst)* **5**: 1489–1494
- Nitiss KC, Malik M, He X, White SW, Nitiss JL (2006) Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage. *Proc Natl Acad Sci USA* **103**: 8953–8958
- Nouspikel T, Hanawalt PC (2002) DNA repair in terminally differentiated cells. *DNA Repair (Amst)* **1**: 59–75
- Ogrunc M, Sancar A (2003) Identification and characterization of human MUS81-MMS4 structure-specific endonuclease. *J Biol Chem* **278**: 21715–21720
- Olive PL, Wlodek D, Durand RE, Banath JP (1992) Factors influencing DNA migration from individual cells subjected to gel electrophoresis. *Exp Cell Res* **198**: 259–267
- Pommier Y (2004) Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camp-

- tothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints. *Curr Med Chem Anti-Canc Agents* **4**: 429–434
- Pouliot JJ, Robertson CA, Nash HA (2001) Pathways for repair of topoisomerase I covalent complexes in *Saccharomyces cerevisiae*. *Genes Cells* **6**: 677–687
- Pourquier P, Pommier Y (2001) Topoisomerase I-mediated DNA damage. *Adv Cancer Res* **80**: 189–216
- Sestili P, Martinelli C, Stocchi V (2006) The fast halo assay: an improved method to quantify genomic DNA strand breakage at the single-cell level. *Mutat Res* **607**: 205–214
- Singh NP, McCoy MT, Tice RR, Schneider EL (1988) A simple technique for quantitation of low levels of DNA damage in individual cells. *Exp Cell Res* **175**: 184–191
- Subramanian D, Kraut E, Staubus A, Young DC, Muller MT (1995) Analysis of topoisomerase I/DNA complexes in patients administered topotecan. *Cancer Res* **55**: 2097–2103
- Takashima H, Boerkoel CF, John J, Saifi GM, Salih MA, Armstrong D, Mao Y, Quijcho FA, Roa BB, Nakagawa M, Stockton DW, Lupski JR (2002) Mutation of TDP1, encoding a topoisomerase I-dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy. *Nat Genet* **32**: 267–272
- Vance JR, Wilson TE (2002) Yeast Tdp1 and Rad1–Rad10 function as redundant pathways for repairing Top1 replicative damage. *Proc Natl Acad Sci USA* **99**: 13669–13674
- Weimer LH, Podwall D (2006) Medication-induced exacerbation of neuropathy in Charcot Marie Tooth disease. *J Neurol Sci* **242**: 47–54
- Yang SW, Burgin Jr AB, Huizenga BN, Robertson CA, Yao KC, Nash HA (1996) A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases. *Proc Natl Acad Sci USA* **93**: 11534–11539
- Zhou T, Lee JW, Tatavarthi H, Lupski JR, Valerie K, Povirk LF (2005) Deficiency in 3'-phosphoglycolate processing in human cells with a hereditary mutation in tyrosyl-DNA phosphodiesterase (TDP1). *Nucleic Acids Res* **33**: 289–297
- Zhuang Y, Fraga CH, Hubbard KE, Hagedorn N, Panetta JC, Waters CM, Stewart CF (2006) Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. *Cancer Res* **66**: 11305–11313